News
Canada’s Drug Agency is recommending that public drug plans pay for a treatment shown to slow the progression of early-stage Alzheimer’s disease if patients meet certain conditions. Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.Health Canada approved it last October, but Canada’s drug agency recommended against publicly funding it in February due to concerns about effectiveness and possible side effects of brain swelling or bleeding.But after reconsidering at the request of the drug’s manufacturer, Eisai, the agency’s expert committee found it may have underestimated…
A blue wave has crashed into the United States. Scottish fans — back at the…
The federal government on Tuesday asked a judge to halt the United States’ first reparations…
Zhu and the HiiKo Drum Group have also released apologies.“Going forward, we will study and…
NEWYou can now listen to Fox News articles! Officials on Tuesday released new details about…
Published on 17/06/2026 – 8:49 GMT+2 The German government is reportedly preparing for its armed…
A federal judge who was disciplined after an investigation found that she had sex with a…
SINGAPORE: Authorities are looking into a cyberattack on the Singapore-based Global Schools Foundation, which operates…
SaveYou have reached your maximum number of saved items.Remove items from your saved list to…
Published on 17/06/2026 – 9:33 GMT+2 As the 2026 World Cup gets underway, FIFA President…
An Alaska woman says a pistol she was carrying helped save her dog’s life after a black…
Millions of animals fall victim to dog and cat thieves in Vietnam who snatch animals…
Police in Medicine Hat say an 11-year-old child who went missing at Echo Dale Regional…
2026 © Prices.com LLC. All Rights Reserved.